Combination of multiple omics techniques for a personalized therapy or treatment selection

Chiara Massa; Barbara Seliger

doi:10.3389/fimmu.2023.1258013

Combination of multiple omics techniques for a personalized therapy or treatment selection

Front Immunol. 2023 Sep 27:14:1258013. doi: 10.3389/fimmu.2023.1258013. eCollection 2023.

Authors

Chiara Massa¹, Barbara Seliger^{1

2

3}

Affiliations

¹ Institute for Translational Immunology, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
² Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
³ Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.

Abstract

Despite targeted therapies and immunotherapies have revolutionized the treatment of cancer patients, only a limited number of patients have long-term responses. Moreover, due to differences within cancer patients in the tumor mutational burden, composition of the tumor microenvironment as well as of the peripheral immune system and microbiome, and in the development of immune escape mechanisms, there is no "one fit all" therapy. Thus, the treatment of patients must be personalized based on the specific molecular, immunologic and/or metabolic landscape of their tumor. In order to identify for each patient the best possible therapy, different approaches should be employed and combined. These include (i) the use of predictive biomarkers identified on large cohorts of patients with the same tumor type and (ii) the evaluation of the individual tumor with "omics"-based analyses as well as its ex vivo characterization for susceptibility to different therapies.

Keywords: biomarker; cancer; high throughput technologies; patient stratification; personalized therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Humans
Immunotherapy* / methods
Neoplasms* / genetics
Neoplasms* / therapy
Tumor Microenvironment / genetics

Substances

Biomarkers, Tumor

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported from Integrate (the German Cancer Aid, grant #70113450 to BS).